GD Power Development (600795.SH) is involved in investing and constructing the Saudi Fifth Round Sadawi 2 million kilowatt solar project.
State Power Investment Corporation (Stock code: 600795.SH) Announcement: On January 16, 2025, the company held the 34th meeting of the eighth board of directors...
GD Power Development (600795.SH) announcement, on January 16, 2025, the company held the thirty-fourth meeting of the eight board of directors, reviewing and approving the proposal "Regarding the participation in the investment and construction of the fifth round of the 200-megawatt Sadahwi photovoltaic project in Saudi Arabia". The project is located in the eastern province of Sadawi in Saudi Arabia, with a installed capacity of 2,000,000 kilowatts. Preliminary work such as project system design, transmission engineering, plant location, land use, and investment structure have been finalized.
The project is jointly invested and constructed by the company's wholly-owned subsidiary GD Power Development Hong Kong Company, with Future Energy Company of Abu Dhabi and Korea Electric Power Corporation. GD Power Development Hong Kong Company holds a 40% stake in the project. The total dynamic investment of the project is 111,169.38 million US dollars, with a capital proportion of approximately 32.38%. Based on the dynamic total investment and share ratio, the company will allocate approximately 143,986.6 million US dollars in capital to GD Power Development Hong Kong Company. Calculated based on a 25-year operating period, an average annual electricity generation of 60.03 billion kilowatt-hours, and a levelized electricity price of 1.292629 US cents per kilowatt-hour, the return on investment for the joint venture project meets the company's requirements.
Related Articles

Jiangsu Hengrui Pharmaceuticals (01276) and Novo Nordisk Enter into an Exclusive Licensing Agreement for HRS-1596, a Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist

HK Stock Market Move | CARSGEN-B(02171) rose over 3% in the afternoon; CT1190B completed the first patient infusion in its Phase I registrational clinical trial in China.

HK Stock Market Move | XUANZHUBIO-B (02575) surged 20% in the afternoon; the company previously announced preliminary discussions regarding a potential acquisition.
Jiangsu Hengrui Pharmaceuticals (01276) and Novo Nordisk Enter into an Exclusive Licensing Agreement for HRS-1596, a Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist

HK Stock Market Move | CARSGEN-B(02171) rose over 3% in the afternoon; CT1190B completed the first patient infusion in its Phase I registrational clinical trial in China.

HK Stock Market Move | XUANZHUBIO-B (02575) surged 20% in the afternoon; the company previously announced preliminary discussions regarding a potential acquisition.






